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Background: Few cases or peri-implant peripheral giant cell lesions (PGCL) have been reported in the literature. 
The aim of this study was to report 13 new cases of peri-implant PGCL and compare the expression of smooth 
muscle actin, Bcl-2 protein, GLUT-1, CD68, osteoprotegerin, receptor activator of nuclear factor kappa-B, Ki-67 
and CD34 in these cases with PGCL and central giant cell lesions (CGCL).
Material and Methods: Clinical data were retrieved from the laboratory records and histological analysis was 
performed using HE-stained slides. Immunohistochemical reactions for the above mentioned antibodies were 
performed and digitally scored.
Results: Peri-implant PGCL mostly affected the posterior mandible of adult females. CD68 and Bcl-2 expressions 
were higher in conventional PGCL and CGCL than in peri-implant PGCL (p=0.033 for CD68 and p<0.0001 
for Bcl-2). Microvessel density was higher in conventional peripheral than in central and peri-implant PGCL 
(p=0.002). Proliferative index of the mononuclear cells showed no statistically significant differences comparing 
the three groups but it was higher in peri-implant PGCL.
Conclusions: The current study demonstrated that peri-implant PGCL is more common in the posterior mandible 
of adult females. There were some differences in microvessel density, proliferative activity and expression of 
CD68 and Bcl-2 among conventional PGCL, peri-implant and CGCL. Further studies are encouraged to better 
understand these early findings.
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Introduction
Peripheral giant cell lesions (PGCL) are relatively com-
mon proliferative growths that affect mainly the lower 
posterior gingiva and edentulous areas of the alveolar 
mucosa (1). It is well accepted that these lesions are 
reactive processes microscopically characterized by 
a proliferation of multinucleated giant cells (possibly 
osteoclast-like type derived from the periodontal liga-
ment) associated with inflammatory mononuclear cells, 
mesenchymal cells, and variable amounts of blood ves-
sels, hemorrhage and fibroblasts (1,2). Local irritative 
factors and chronic trauma are the main etiological fac-
tors recognized to date (2). Central giant cell lesions 
(CGCL) are intraosseous conditions that occur mainly 
in the mandible and are histologically similar to PGCL 
(3). The exact pathogenesis of CGCL is still controver-
sial and its etiology has not been fully elucidated, but 
some lesions histologically identical to CGCL are asso-
ciated with other entities, such as hyperparathyroidism, 
cherubism, Noonan syndrome, and type-1 neurofibro-
matosis (4,5).
Almost all PGCL are associated with teeth or arise in 
edentulous areas of the alveolar mucosa, but there are 
also some few reported cases of peri-implant PGCL (1). 
Conventional PGCL, peri-implant PGCL and CGCL 
are histologically similar, but their pathogenesis re-
mains poorly understood. The immunoprofile of PGCL 
and CGCL has been widely investigated and expres-
sion of numerous markers for proliferative activity, os-
teoclast metabolism, angiogenesis and apoptosis have 
been studied in these lesions (6-9). However, there is 
no previously published comparative study including 
peri-implant PGCL and it is not known whether the ex-
pression of metabolism markers and proteins involved 
in osteoclast activation pathways and apoptosis can be 
different when comparing these 3 groups. Therefore, 
the aim of the present study was to describe the clinico-
pathological features of a series of peri-implant PGCL 
and to compare the histological and immunohistochem-
ical profile of conventional and peri-implant PGCL and 
CGCL.
Material and Methods
The sample consisted of 36 specimens retrieved from 
the files of the Oral Pathology Laboratory, School of 
Dentistry, State University of Rio de Janeiro, Brazil 
and from the Oral & Maxillofacial Pathology Labora-
tory, University of the Basque Country/EHU, Leioa, 
Spain. After analysis of the integrity of the specimen 
and its representativeness, the cases were selected and 
grouped in CGCL (n=10), conventional PGCL (n=13) 
and peri-implant PGCL (n=13). Clinical, radiologi-
cal and gross specimen data from each case were ob-
tained from the laboratory registries and histological 
features were described after analysis of five-µm HE-
stained sections. This study was approved by the Insti-
tutional Board Review of the Piracicaba Dental School, 
University of Campinas (CEP/FOP; process number 
70503317.8.0000.5418).
Immunohistochemical (IHC) reactions were per-
formed using 3-µm sections deparaffinized in xylene 
and hydrated in graded series of alcohol. Antigen re-
trieval was performed with a citric acid solution (pH 
6.0) (α-Smooth muscle actin - α-SMA, Bcl-2, Glucose 
transporter 1 - Glut-1, CD68, and CD34) or EDTA/Tris 
solution (osteoprotegerin – OPG, receptor activator of 
nuclear factor kappa-B – RANK, and Ki-67) and pres-
sure cooker. The activity of the endogenous peroxidase 
was blocked with one 15-minute bath of 10% hydrogen 
peroxide. The sections were incubated for 2 hours with 
the primary antibodies against α-SMA (clone 1A4, di-
lution 1:400, positive control – endometrium, Dako, 
Carpinteria, CA, USA), Bcl-2 (clone 124, dilution 1:50, 
positive control – lymph node, Dako, Carpinteria, CA, 
USA), Glut-1 (polyclonal, dilution 1:100, positive con-
trol – fibrous hyperplasia, BioSystems, Evry cedex, 
France), CD68 (clone PG-M1, dilution 1:400, positive 
control – mucocele, Dako, Carpinteria, CA, USA), OPG 
(clone ab183910, dilution 1:100, positive control – newly 
formed bone tissue, Abcam, Cambridge, MA, USA), 
RANK (clone 64c1385, dilution 1:100, positive control 
– newly formed bone tissue, Abcam, Cambridge, MA, 
USA), CD34 (clone QBEnd-10, dilution 1:50, positive 
control – pyogenic granuloma, Dako, Carpinteria, CA, 
USA) and Ki-67 (clone MIB-1, dilution 1:100, positive 
control – lymphoma, Dako, Carpinteria, CA, USA). Af-
ter that, the sections were incubated with the super-sen-
sitive non-biotin based IHC visualization system (Ad-
vanceTM HRP Kit – DakoCytomation, Carpinteria, CA, 
USA). Diaminobenzidine tetrahydrochloride (DAB, 
Sigma, St. Louis, MO, USA) was used as chromogen 
and was followed by counterstaining with Carazzi’s he-
matoxylin.
All HE-stained and IHC slides were scanned into high-
resolution images using the Aperio Scanscope CS 
Slide Scanner (Aperio Technologies Inc., Vista, Cali-
fornia, USA). For α-SMA, Bcl-2, Glut-1, CD68, OPG 
and RANK, the Positive Pixel Count v9 (Aperio Tech-
nologies Inc.) algorithm classified staining in negative, 
weak-positive, medium-positive and strong-positive; 
five distinct medium-power fields were evaluated for 
each case. The final score of each marker for each le-
sion was calculated as the sum of the percentage of each 
category multiplied by their intensity scores using the 
following formula: [tumor score = (percentage weak 
× 1) + (percentage moderate × 2) + (percentage strong 
× 3)]. The results ranged from 100 to 300, which was 
in agreement with previous study from our group (10). 
For Ki-67, the Nuclear Algorithm (Aperio Technologies 
Inc.) detected the total, negative and positive nuclear 
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Table 1: Clinical and demographic data and mean number (standard deviation) of multinucleated giant cells (MGC) and mono-
nuclear cells (MC) per high-power field, and proportion of mononuclear/giant cells in central giant cell lesions (CGCL) and conven-
tional and peri-implant peripheral giant cell lesions (PGCL). 
staining, generating an index of the positivity (in %), 
and it was also calculated for the surface epithelium. 
Microvessel density, assessed by counting the total of 
CD34-positive vessels, was performed by the software 
Microvessel Analysis Algorithm (Aperio Technologies 
Inc.). The ratio of giant/mononuclear cells was also cal-
culated for each case. All histomophometric and digital-
IHC analyzes were carried out in five high-power fields 
(×40 magnification) and the mean was calculated.
Statistical Package for Social Sciences (SPSS) soft-
ware version 22 (IBM, Chicago, IL, USA) was used 
for statistical analysis. Normality was analyzed with 
the Kolmogorov-Smirnov test. Kruskal-Wallis test was 
applied to compare the means from all scores, cellular 
proliferative index and microvessel density. Data were 
also examined through the Pearson correlation test. The 
level of significance was considered 5% (p ≤ 0.05) for 
all analyses.
Results
Peri-implant PGCL affected mostly females (11 cases 
– 85%) and mean age of the patients was 57.5 years 
(ranging from 29 to 73 years old). Ten cases affected 
the mandible (77%) and 70% of the cases were located 
in the posterior region. Clinical aspect of the lesions 
was described as a reddish/purplish growth in 62% of 
the cases and most cases presented less than 15 mm in 
size in its greater diameter. Clinical diagnosis included 
mostly pyogenic granuloma (in 10 cases) and PGCL 
was suspected in only two cases. Clinical and demo-
graphical characteristics comparing the three groups 
are shown in Table 1.
CGCL and peri-implant PGCL demonstrated a pre-
dilection for females while conventional PGCL were 
more common in males. Mean age of the patients af-
fected by PGCL was higher than the mean age of the 
CGCL-affected patients. All three groups were more 
common in the mandible and most PGCL were smaller 
than the CGCL (Table 1).
All lesions showed a similar histological pattern. Con-
ventional and peri-implant PGCL were mostly covered 
by a keratinized stratified squamous epithelium, with a 
higher frequency of ulceration in peri-implant PGCL. 
The lamina propria was composed by a loose connec-
tive tissue and the deeper parts of the stroma showed a 
proliferation of multinucleated giant cells interspersed 
by a component of ovoid and spindled shaped mes-
enchymal cells and numerous small blood vessels. In 
CGCL, a spindle cell proliferation was also present 
and multinucleated giant cells were observed in direct 
contact with bone trabeculae. Multiple areas of hemor-
rhage and presence of hemosiderin were also common 
in CGCL (Fig. 1). Mean number of multinucleated gi-
ant cells per high-power field (×40 magnification) was 
50.25, 52.08 and 56.76 for CGCL, conventional PGCL 
and peri-implant PGCL, respectively. Proportion of 
ovoid/spindled mononuclear mesenchymal cells to mul-
tinucleated giant cells was 53.96, 45.57 and 44.37 for 
CGCL, conventional PGCL and peri-implant PGCL, re-
spectively. Differences were not statistically significant 
(Table 1).
The IHC features showed that α-SMA was expressed 
in blood vessels and myofibroblasts in all groups. Bcl-2 
demonstrated a variable expression in mononuclear cells 
Parameter CGCL Conventional PGCL Peri-implant PGCL
Gender   
Male 3 (30%) 8 (62%) 2 (15%)
Female 7 (70%) 5 (38%) 11 (85%)
Age (years)   
Mean 28.8 54.5 57.5
Range 11 – 85 9 – 86 29 – 73
Site   
Maxilla 2 (20%) 5 (38%) 3 (23%)
Mandible 8 (80%) 8 (62%) 10 (77%)
Size
≤ 15 mm 3 (30%) 9 (69%) 8 (62%)
> 15 mm 7 (70%) 4 (31%) 5 (38%)























* p = 0.69; ** p = 0.55; *** p = 0.66 (ANOVA).
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and multinucleated giant cells. Several cases showed a 
weak expression of Bcl-2 in multinucleated giant cells. 
Ulcerated conventional and peri-implant PGCL showed 
a higher number of inflammatory cells positive for Bcl-
2 close to areas of ulceration. Glut-1 was expressed in 
the cytoplasm of few multinucleated giant cells in all 
groups and surface epithelium in conventional and 
peri-implant PGCL. CD68 was expressed mainly in the 
cytoplasm of the multinucleated giant cells and some 
disperse mononuclear cells. RANK and OPG demon-
strated a cytoplasmic expression in fusiform and mono-
nuclear cells, and some giant cells were also strongly 
positive for both markers. CGCL presented higher ex-
pression of RANK than conventional and peri-implant 
PGCL, while OPG was more expressed in peri-implant 
PGCL than in conventional PGCL and CGCL. CD34 
was expressed mainly in the endothelial cells of large 
and small vessels and occasionally in dispersed fusi-
form cells, compatible with fibroblasts/myofibroblasts. 
Fig. 1 and Fig. 2 show some histological features of the 
studied lesions as well as the comparative immunoex-
pression of α-SMA, Bcl-2, Glut-1, CD68, RANK, OPG 
and CD34.
The proliferative index of the mononuclear ovoid/spin-
dled mesenchymal cells, assessed by Ki-67-positive nu-
clei was 5.33%, 5.24% and 6.49% for CGCL, convention-
al PGCL and peri-implant PGCL, respectively (Fig. 2).
Overall, in peripheral lesions the proliferative index 
of the surface epithelium was 11.16% for conventional 
PGCL and 22.49% for peri-implant PGCL. The epithe-
lial proliferative index in non-ulcerated conventional 
PGCL was 11.35% (10/13 cases) and ulcerated was 
10.53% (3/13 cases). Regarding the peri-implant PGCL 
the values were 18.31% for non-ulcerated lesions (3/13 
cases) and 23.75% for ulcerated lesions (10/13 cases).
Mean scores from the digital analysis for all studied 
markers are shown in Fig. 3.
Fig. 1: Histological features and immunohistochemical expression 
of α-SMA, Bcl-2, Glut-1 and CD68 in CGCL (central giant cell le-
sions), conventional and peri-implant PGCL (peripheral giant cell 
lesions) (All 400x magnification).
Fig. 2: Immunohistochemical expression of RANK, OPG, CD34 
and Ki67 in CGCL (central giant cell lesions), and conventional and 
peri-implant PGCL (peripheral giant cell lesions) (All 400x magni-
fication).
Fig. 3: Comparison of the expression of the studied markers in the 
three groups: CGCL (central giant cell lesions), PGCL (conventional 
peripheral giant cell lesions) and PGCL/implants (peri-implant pe-
ripheral giant cell lesions) (Statistically significant differences are 
shown by asterisks).
CD68 and Bcl-2 scores were higher in conventional 
PGCL and CGCL than in peri-implant PGCL (P=0.033 
for CD68 and P<0.0001 for Bcl-2). Microvessel den-
sity was higher in conventional PGCL than in CGCL 
and peri-implant PGCL (P=0.002). The α-SMA, Glut-
1, RANK and OPG scores demonstrated a similar ex-
pression in the three groups, without any statistically 
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significant differences. Correlation tests demonstrated 
a positive correlation between microvessel density and 
the expression of CD68 (r= 0.360, P=0.034) and OPG 
(r=0.382, P=0.024).
Discussion
Most studies have demonstrated that oral mucosal and 
gnathic giant cell lesions show a similar histological pat-
tern and are considered reactive entities, although they 
sometimes present a local aggressive clinical course (3-
5). They can affect the gnathic bones and the gingiva/
alveolar mucosa and can rarely be associated with den-
tal implants (1,3,11). Several studies have compared the 
clinicopathological and immunohistochemical features 
of PGCL and CGCL, mostly directed to proliferative 
pattern and histogenetic origin of the multinucleated gi-
ant cells and mononuclear spindle cells (6-9). As far as 
we know, this is the first study focusing these histologi-
cal and immunohistochemical comparisons including 
peri-implant PGCL.
There are less than 30 cases of peri-implant PGCL re-
ported in the English-language literature since its first 
description by Hirshberg et al. in 2003 (11-25). Apart 
from isolated case reports, only one previous compara-
tive study has included 9 cases of peri-implant PGCL 
(25). The present series is the largest reported up to now 
and possibly includes a representative comparative pro-
file of this condition. The previously published cases 
reinforce the present results showing that peri-implant 
PGCL is more common in the posterior mandible of fe-
males in the fifth to sixth decades of life (11-25). This 
distribution could be explained by the fact that dental 
implants are more commonly installed in the mandible 
of older females. In the present sample, CGCL and peri-
implant PGCL occurred more commonly in the man-
dible of females, in accordance with previous studies 
(18,22,23). Both conventional and peri-implant PGCL 
affected older patients in comparison with CGCL, also 
in accordance with the literature (4,5,18). It is interest-
ing to notice that most cases were clinically interpreted 
as pyogenic granulomas, but clinicians should be aware 
that PGCL can be also associated with dental implants.
The present results showed that both the mean number 
of multinucleated giant cells per high-power field and 
the proportion of ovoid/spindled mononuclear mesen-
chymal cells to multinucleated giant cells were similar 
for CGCL, conventional PGCL and peri-implant PGCL. 
One previous study showed, however, a significantly 
lower number of giant cells and a lower density of mes-
enchymal cells in peri-implant PGCL in comparison 
with conventional PGCL (25). It is possible that the 
low number of cases could bias these findings and more 
studies including larger samples are necessary to under-
stand these initial observations.
CD68 is a transmembrane glycoprotein widely used as 
a specific marker of cells of the monocyte-macrophage 
lineage, such as monocytes, histiocytes and osteoclasts. 
We observed a higher CD68 expression score in CGCL 
and conventional PGCL than in peri-implant PGCL. 
Conventional PGCL demonstrated a higher CD68 ex-
pression score in comparison with CGCL, although 
not statistically significant, in accordance with previ-
ous results (8). An intriguing result from our study was 
the higher number of giant cells but lower expression 
of CD68 in peri-implant PGCL in comparison with the 
other two groups. It has been demonstrated that imma-
ture mononuclear cells derived from the bone marrow 
do not express CD68, and their stimulation by macro-
phage colony-stimulating factor is time-dependent (26), 
so osteoclasts in these lesions can be derived exclusively 
from the bone in the area adjacent to the implant. CD68-
deficient osteoclasts have demonstrated lower resorp-
tion activity and, in some instances, stimulates osteo-
blasts (26). Thus, we can suggest that CD68-deficient 
osteoclasts are more common in peri-implant PGCL 
due to the absence of periodontal ligament. However, 
we were not able to explain if osteoclasts of conven-
tional PGCL have higher resorption activity and, conse-
quently, demonstrate higher CD68-expression.
Macrophages are potent angiogenic stimulators by 
producing several angiogenic factors and our results 
showed a positive correlation between the expression 
of CD68 and microvessel density. Conventional PGCL 
showed both a higher microvessel density and a higher 
score of CD68-positive cells than peri-implant PGCL; 
one explanation for these findings could be that conven-
tional PGCL is exposed to continuous local irritative 
factors from the periodontal ligament or local trauma, 
showing an increase in the number of blood vessels and, 
consequently, a higher microvessel density. Higher mi-
crovessel density has been also associated with a more 
aggressive phenotype of CGCL (27), but we were not 
able to evaluate this possible association due to the 
methods used in the present study.
Several components of the B-cell lymphoma family, 
particularly Bcl-2, have been involved in the apoptotic 
pathway, acting as positive or negative regulators of this 
process (28). It is well established that Bcl-2 facilitates 
cell survival, playing an important role in tumor initia-
tion and maintenance (9,28). Expression of Bcl-2 was 
previously demonstrated in multinucleated giant cells 
from both PGCL and CGCL (9,28) and, in the present 
study, its expression was significantly lower in peri-
implant PGCL in comparison with the other groups. It 
seems that the influence of apoptotic factors is less im-
portant in the growth and maintenance of peri-implant 
PGCL than conventional PGCL, but further investiga-
tions with larger samples and including other proteins 
involved in the apoptotic pathway are encouraged to 
clarify the importance of these findings.
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RANK pathway is directly involved in the dynamics of 
osteoclastogenesis, playing an important role in osteo-
clast proliferation, activation and apoptosis (29). On the 
other hand, OPG acts as an inhibitor of the osteoclast 
activity. In the current study, RANK and OPG present-
ed similar digital scores in all three groups, suggesting 
that these markers exert an important role in the histo-
genesis of multinucleated giant cells in giant cell lesions 
independent from its origin (peripheral or central) and 
relationship to periodontal ligament or not.
Expression of α-SMA was similar in the three groups 
suggesting that the presence of cells with myofibroblas-
tic phenotype is constant in GCL and is not dependent 
on origin and relationship to periodontal ligament. Glut-
1 is a molecule involved in the basal glucose uptake and, 
consequently, plays an important role in the cellular me-
tabolism, energy production and intracellular glucose 
concentration levels (30). Its expression was also similar 
in the three groups and apparently does play a specific 
origin-dependent role in the pathogenesis of giant cell 
lesions.
Comparison of the proliferative index of the mononu-
clear cells from the three groups showed no statistically 
significant differences. However, the proliferative index 
was higher in peri-implant PGCL than in conventional 
PGCL and CGCL. The higher proliferative index of the 
peri-implant PGCL could be associated with the higher 
frequency of ulceration of the surface epithelium seen 
in this group and seems to be not associated with apop-
totic pathways. Peri-implant PGCL have demonstrated 
higher intralesional and epithelial proliferative index in 
comparison with conventional PGCL and CGCL, to-
gether with lower expression of Bcl-2 compared with 
the other lesions.
In conclusion, the results of the current study showed 
that peri-implant PGCL are more common in the pos-
terior mandible of adult females. We have also demon-
strated some differences in microvessel density, pro-
liferative activity and expression of CD68 and Bcl-2 
among conventional PGCL, peri-implant PGCL and 
CGCL. Although this series is the largest reported up 
to now, the present study has some limitations in data 
interpretation such as the limited number of cases and 
the difficulties in obtaining information on follow-up, 
limiting the discussion about biological behavior of 
peri-implant PGCL. Further studies with larger series 
with follow-up and inclusion of additional histogenetic 
markers are encouraged to better understand these early 
findings. 
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